ENVB vs. SHPH, TFFP, ADIL, PULM, CVKD, XBIO, ADXS, KTTA, LIXT, and VCNX
Should you be buying Enveric Biosciences stock or one of its competitors? The main competitors of Enveric Biosciences include Shuttle Pharmaceuticals (SHPH), TFF Pharmaceuticals (TFFP), Adial Pharmaceuticals (ADIL), Pulmatrix (PULM), Cadrenal Therapeutics (CVKD), Xenetic Biosciences (XBIO), Ayala Pharmaceuticals (ADXS), Pasithea Therapeutics (KTTA), Lixte Biotechnology (LIXT), and Vaccinex (VCNX). These companies are all part of the "pharmaceutical preparations" industry.
Enveric Biosciences (NASDAQ:ENVB) and Shuttle Pharmaceuticals (NASDAQ:SHPH) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, community ranking, valuation, earnings, analyst recommendations and media sentiment.
Enveric Biosciences currently has a consensus price target of $10.00, indicating a potential upside of 1,023.60%. Given Enveric Biosciences' higher probable upside, equities research analysts clearly believe Enveric Biosciences is more favorable than Shuttle Pharmaceuticals.
Shuttle Pharmaceuticals is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks.
Enveric Biosciences received 5 more outperform votes than Shuttle Pharmaceuticals when rated by MarketBeat users.
Enveric Biosciences has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500. Comparatively, Shuttle Pharmaceuticals has a beta of -1.18, meaning that its share price is 218% less volatile than the S&P 500.
13.8% of Enveric Biosciences shares are held by institutional investors. Comparatively, 4.6% of Shuttle Pharmaceuticals shares are held by institutional investors. 1.2% of Enveric Biosciences shares are held by insiders. Comparatively, 40.6% of Shuttle Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
In the previous week, Enveric Biosciences had 3 more articles in the media than Shuttle Pharmaceuticals. MarketBeat recorded 3 mentions for Enveric Biosciences and 0 mentions for Shuttle Pharmaceuticals. Shuttle Pharmaceuticals' average media sentiment score of 0.00 beat Enveric Biosciences' score of -0.11 indicating that Shuttle Pharmaceuticals is being referred to more favorably in the news media.
Shuttle Pharmaceuticals' return on equity of -112.18% beat Enveric Biosciences' return on equity.
Summary
Enveric Biosciences beats Shuttle Pharmaceuticals on 7 of the 13 factors compared between the two stocks.
Get Enveric Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENVB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ENVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Enveric Biosciences Competitors List
Related Companies and Tools
